Essilor: Procedures for Requesting or Viewing Proxy Information for the Combined Ordinary and Extraordinary Annual Meeting on

  Essilor: Procedures for Requesting or Viewing Proxy Information for the
  Combined Ordinary and Extraordinary Annual Meeting on May 16, 2013

Business Wire

CHARENTON-LE-PONT, France -- April 5, 2013

Regulatory News:

Essilor (Paris:EI) :

Shareholders are advised that the Combined Ordinary and Extraordinary Annual
Meeting will be held on Thursday, May 16, 2013 at 10:30 am CEST at Palais des
Congrès de Paris, 2 place de la Porte Maillot, 75 017 Paris, France.

The preliminary notice of meeting, published in the Bulletin des Annonces
Légales Obligatoires on April 5, 2013, contains information on the agenda, the
proposed resolutions and the procedures for attending and voting.

Proxy information may be viewed in the Investors section of the Essilor
corporate website at http://www.essilor.com: “Individual Shareholders
Information / Annual Shareholders’ Meeting”.

As provided for in articles R.225-88 and R.225-89 of the French Commercial
Code, any shareholder may consult the proxy documents and information, as
described in article R.225-83 of the French Commercial Code, at Company
headquarters (147 rue de Paris, 94220 Charenton-le-Pont, France) or request
that such documents be sent to him or her, by writing to Société Générale,
Service des Assemblées, 32 rue du Champ de Tir, BP 81236 – 44 312 Nantes Cedex
3, France.

About Essilor

The world’s leading ophthalmic optics company, Essilor designs, manufactures
and markets a wide range of lenses to improve and protect eyesight. Its
corporate mission is to enable everyone around the world to access lenses that
meet his or her unique vision requirements. To support this mission, the
Company allocates more than €150 million to research and innovation every
year, in a commitment to continuously bring new, more effective products to
market. Essilor’s flagship brands are Varilux^®, Crizal^®, Definity^®,
Xperio^®, Optifog^TM and Foster Grant^®. It also develops and markets
equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of approximately €5 billion in 2012 and
employs around 50,700 people in some 100 countries. It operates 22 plants,
more than 400 prescription laboratories and edging facilities, as well as
several research and development centers around the world.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in
the Euro Stoxx 50 and CAC 40 indices.

Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Contact:

Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16